CD20, a critical membrane marker of B-cell lymphocytes, has revolutionized the treatment of B-cell malignancies. As a crucial target for monoclonal antibodies targeting cancer immunotherapy, CD20 gained prominence with the approval of rituximab, the first antibody treatment for lymphoma. This integral membrane protein, belonging to the MS4A family, plays a crucial role in the management of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite its significance, CD20's exact function remains elusive, making it a subject of intense research and scientific curiosity.
Our study focuses on the extraction and purification of native CD20 from different cell lines. We successfully purified native, full-length CD20 from cancer cell membranes using a cutting-edge proprietary Eurofins CALIXARene-based detergent approach.
Size exclusion chromatography and SDS-PAGE analysis demonstrated that our native purified CD20 maintains its binding affinity for both rituximab and obinutuzumab. The distinct elution profiles of the antibody-CD20 complexes indicate successful binding, while SDS-PAGE analysis further validates the presence of both components in the complexes. These findings underscore the effectiveness of SEC in characterizing antibody interactions with CD20, which is crucial for understanding therapeutic strategies in treating CD20-positive malignancies.
This innovative method improves CD20 protein yield, ensuring non-aggregated, concentration-dependent oligomerization, and overcoming previous limitations in CD20 isolation. The availability of purified full-length CD20 opens new avenues for detailed structural & functional studies and CD20-antibody interactions, potentially leading to the development of more effective therapeutics. Our purified CD20 bridges the gap between earlier peptide-based studies and the full protein context, offering invaluable insights that could revolutionize our approach to B-cell lymphomas. Furthermore, our product aids in investigating the regulation of the CD20 gene and protein at both pre- and post-transcriptional levels, contributing to a more comprehensive understanding of B-cell lymphomas and accelerating the creation of next-generation targeted therapies. By providing researchers with a reliable tool for CD20 studies, we are committed to advancing B-cell targeted therapies. This research has the potential to improve treatment outcomes for millions of patients suffering from lymphomas, leukemias, and autoimmune diseases, reinforcing our dedication to innovation and excellence in the field of biotherapeutics.
While specific structural insights into CD20 remain elusive, the purified protein forms confined nanodroplets that do not aggregate. This stable, non-aggregated state of CD20 is a significant advancement, bridging the gap between earlier peptide-based studies and the full protein context. The insights gained from this work could revolutionize our approach to B-cell lymphomas and accelerate the creation of next-generation targeted therapies.
References :
Morgane A. et al. 2019
Desuzinges Mandon E. et al. 2017
